Near-Infrared Spectroscopy Measurements in Chronic Obstructive Pulmonary Disease
NCT ID: NCT06976762
Last Updated: 2025-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
140 participants
OBSERVATIONAL
2025-05-01
2025-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Change in Airway Peripheral Tone in COPD
NCT04166812
Comparison of Clinical Status of Individuals with COPD and Preserved Ratio Impaired Spirometry
NCT06682832
Respiratory Muscle Function, Diaphragm Thickness and Health Related Physical Fitness Parameters in Individuals
NCT04995510
Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison
NCT02076269
Prediction of COPD Severity Using Electrical Impedance Tomography
NCT06359145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Data collection involved baseline assessments of demographic characteristics, COPD severity, renal function, and comorbidities. Participants were divided into three groups: control, COPD, and CRD. Patients were visited during their stay in the ward and the measurement was initiated after five minutes of rest. Venous blood gas analysis was performed using the same sample of blood obtained for routine complete blood count analysis. A vascular occlusion test was conducted with NIRS measurements taken throughout. Three minutes of baseline measurement placing the probe on thenar eminence of the right hand was completed while the patient was lying with 45 degrees back up position. After baseline measurements a non-invasive blood pressure cuff was placed on the right arm and it was inflated to 250 mmHg. The cuff was held inflated for two minutes; after two minutes, the cuff was deflated and the measurement had been continued for another three minutes and stopped. Near-infrared spectroscopy measurements were obtained during and after vascular occlusion, including the area under curve (AUC) during occlusion (representing tissue hyperemia) and the angles of descent and ascent, which reflect muscle oxygen consumption and microcirculatory function, respectively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COPD
Patients with aged between 18 and 80 years, a confirmed diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, a post-bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio of \<0.70, and clinically stable COPD, with no exacerbations or hospital admissions within the preceding four weeks were enrolled in this COPD group.
No interventions assigned to this group
CKD
Patients with aged between 18 and 80 years, evidence of CKD, an estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73 m² (Stages 3-5 CKD) on at least two occasions three months apart, or a history of renal replacement therapy were enrolled in CKD group.
No interventions assigned to this group
Control
Healthy individuals
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age: Patients aged between 18 and 80 years.
2. COPD Diagnosis: A confirmed diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, including:
* A post-bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio of \<0.70.
3. Renal Failure: Evidence of CKD, defined as:
* An estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73 m² (Stages 3-5 CKD) on at least two occasions three months apart, or a history of renal replacement therapy.
4. Stable Medical Condition: Clinically stable COPD, with no exacerbations or hospital admissions within the preceding four weeks.
Exclusion Criteria
1. Acute Exacerbation: Evidence of an acute COPD exacerbation within four weeks prior to enrolment.
2. Other Respiratory Disorders: Coexistence of other chronic respiratory diseases such as asthma, interstitial lung disease, or bronchiectasis that might interfere with the assessment of COPD.
3. Renal Transplantation: History of kidney transplantation, as immunosuppressive therapy may affect disease progression and outcomes.
4. Uncontrolled Comorbidities: Presence of any uncontrolled comorbid conditions, including:
* Cardiovascular instability or recent myocardial infarction (within six months).
* Active malignancy (other than localized skin cancer).
* Severe liver disease (e.g., cirrhosis with hepatic failure).
5. Pregnancy or Breastfeeding: Women who were pregnant or breastfeeding at the time of study enrolment.
6. Cognitive Impairment: Any condition that would impair the ability to provide informed consent or participate in study procedures, such as dementia or significant psychiatric disorders.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tokat Gaziosmanpasa University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Serkan Dogru
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel MARTIN, Professor
Role: PRINCIPAL_INVESTIGATOR
Uni of Plymouth, Dept of Periop and ICU, Plymouth, UK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tokat Gaziosmanpasa University
Tokat Province, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-KAEK-212
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.